ERBB2 and breast cancer: Additionally, 52 (23.7%) and 8 (3.7%) HER2+ BC patients received either trastuzumab (loading dose of 8 mg/kg followed by 6 mg/kg in subsequent cycles) ± pertuzumab (loading dose of 840 mg followed by 420 mg in subsequent cycles) in combination with taxanes.